GO:0015350 methotrexate transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015350 describes the molecular function of moving methotrexate, a folate analogue and potent dihydrofolate reductase inhibitor, across a membrane.
• The function is carried out by several distinct transporter families, including the reduced folate carrier (SLC19A1), the proton-coupled folate transporter (SLC46A1), and ATP-binding cassette exporters such as ABCC2 (MRP2) and ABCB1 (P-glycoprotein).
• Methotrexate transport activity is a major determinant of drug sensitivity and resistance in cancer and autoimmune diseases.
• Loss-of-function mutations, such as Trp1254 in MRP2, can abolish methotrexate transport and alter substrate specificity.
• Transport activity can be restored by co-expressing complementary half-molecules or by engineering chimaeric transporters, demonstrating that specific transmembrane domains form the substrate translocation pathway.
• Studying GO:0015350 requires a combination of transport assays, mutagenesis, and CRISPR-based genome editing to link molecular function to cellular phenotypes.
Description
Methotrexate is a widely used antifolate drug that inhibits dihydrofolate reductase and is central to the treatment of cancers, autoimmune disorders, and ectopic pregnancy. Its therapeutic efficacy depends on its ability to cross cell membranes, a process mediated by specific transport proteins. The Gene Ontology term GO:0015350, methotrexate transmembrane transporter activity, captures the molecular function of these proteins that facilitate the movement of methotrexate across biological membranes. Understanding this activity is essential for predicting drug response, overcoming resistance, and designing better antifolate therapies. The transport of methotrexate is mediated by multiple families of membrane proteins, including the reduced folate carrier (RFC/SLC19A1), the proton-coupled folate transporter (PCFT/SLC46A1), and ATP-binding cassette (ABC) transporters such as ABCC2 (MRP2) and ABCB1 (P-glycoprotein). Each transporter has distinct substrate specificities, tissue distributions, and regulatory mechanisms, and their coordinated action determines intracellular drug concentrations. Mutations in these transporters can lead to loss of transport activity, as shown for the Trp1254 mutation in MRP2, which abolishes methotrexate transport. Conversely, co-expression of complementary transporter fragments can restore activity, highlighting the structural requirements for function. This article reviews the molecular mechanisms, key genes, and research methods used to study GO:0015350, with a focus on how CRISPR-based models can elucidate its role in health and disease.
methotrexate transmembrane transporter activity At A Glance
| GO ID | GO:0015350 |
|---|---|
| GO term | methotrexate transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | methotrexate transporter activity |
| Definition | Enables the transfer of methotrexate, 4-amino-10-methylformic acid from one side of a membrane to the other. Methotrexate is a folic acid analogue and a potent competitive inhibitor of dihydrofolate reductase. |
| Major function | Mediates the movement of methotrexate across cell membranes, influencing drug uptake, efflux, and intracellular concentration. |
| Representative genes | SLC19A1 (RFC), SLC46A1 (PCFT), ABCC2 (MRP2), ABCB1 (MDR1), ABCG2 (BCRP) |
| Related diseases | Cancer drug resistance, autoimmune rheumatic diseases, cystic fibrosis (emerging treatments) |
| Research methods | Transport assays, mutagenesis, CRISPR knockout/knock-in, structural biology |
What Is GO:0015350?
GO:0015350, methotrexate transmembrane transporter activity, is a molecular function defined as enabling the transfer of methotrexate (4-amino-10-methylformic acid) from one side of a membrane to the other. Methotrexate is a folic acid analogue and a potent competitive inhibitor of dihydrofolate reductase. This activity is distinct from general folate transport because it specifically describes the movement of methotrexate, although many transporters that recognize methotrexate also transport reduced folates.
Why Is methotrexate transmembrane transporter activity Important in Cell Biology?
Methotrexate transmembrane transporter activity is critical for determining the pharmacokinetics and pharmacodynamics of methotrexate, a first-line drug for numerous cancers and autoimmune conditions. Altered transport activity can lead to drug resistance or toxicity, making these transporters important biomarkers and therapeutic targets.
• Determines intracellular methotrexate levels and thus drug efficacy in cancer and autoimmune diseases.
• Loss-of-function mutations in transporters like ABCC2 cause methotrexate resistance.
• Overexpression of ABCB1 or ABCG2 can confer multidrug resistance, which can be reversed by inhibitors like sildenafil.
• Genetic variation in SLC19A1 and SLC46A1 affects methotrexate response and toxicity.
• Transport activity is essential for methotrexate uptake in tissues such as the intestine and kidney.
• Understanding transport mechanisms aids in the design of novel antifolates with improved uptake.
• Transporters are potential targets for modulating drug resistance in rheumatic diseases.
• CRISPR-based editing of transporter genes enables functional validation in relevant cell models.
Molecular Mechanism of methotrexate transmembrane transporter activity
Substrate recognition and binding
In simple terms: The transporter must first recognize and grab methotrexate on one side of the membrane.
Methotrexate transport begins with substrate recognition by specific transmembrane domains. For the reduced folate carrier (RFC/SLC19A1), substrate binding involves transmembrane domains 7-12, as shown by co-expression of half-molecules that restore transport activity. The proton-coupled folate transporter (PCFT/SLC46A1) uses a reentrant loop between transmembrane domains 2 and 3 for substrate interaction. In MRP2 (ABCC2), mutation of Trp1254 alters substrate specificity and abolishes methotrexate transport, indicating a critical role for this residue in substrate binding.
Translocation across the membrane
In simple terms: After binding, the transporter undergoes conformational changes to move methotrexate across the lipid bilayer.
Translocation is driven by different energy sources depending on the transporter family. RFC functions as an antiporter, exchanging methotrexate for organic anions, while PCFT uses a proton gradient. ABC transporters such as MRP2 and ABCB1 utilize ATP hydrolysis to pump methotrexate out of cells. The transmembrane domain 6/7 linker region in RFC is critical for coupling substrate binding to translocation, as chimaeric transporters with altered linkers show restored transport activity.
Energy coupling and regulation
In simple terms: Some transporters use ATP, others use ion gradients, and their activity can be regulated by cellular signals.
ABC transporters like ABCB1 and ABCG2 are ATP-dependent efflux pumps; their activity can be modulated by inhibitors such as sildenafil, which reverses chemotherapeutic drug resistance. RFC and PCFT are secondary active transporters that rely on ion gradients. Regulation of these transporters occurs at multiple levels, including transcriptional control and post-translational modifications, though specific pathways for methotrexate transporters are still being elucidated.
Substrate specificity and inhibition
In simple terms: Transporters can be selective for methotrexate, but some also transport other drugs, leading to interactions.
Methotrexate transport activity is not always specific; many transporters also recognize folates and other antifolates. MRP2 transports a broad range of organic anions, and the Trp1254 mutation alters its substrate specificity, causing loss of methotrexate transport while retaining other substrates. ABCB1 and ABCG2 are multidrug transporters that can efflux methotrexate and other chemotherapeutics, contributing to cross-resistance.
Key Genes Involved in GO:0015350 methotrexate transmembrane transporter activity
The following genes encode proteins that exhibit methotrexate transmembrane transporter activity or are directly involved in its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC19A1 (RFC) | Major influx transporter for reduced folates and methotrexate | Determines methotrexate uptake; mutations affect drug sensitivity |
| SLC46A1 (PCFT) | Proton-coupled folate transporter; mediates intestinal folate and methotrexate absorption | Important for oral methotrexate bioavailability; structural studies |
| ABCC2 (MRP2) | ATP-dependent efflux pump for organic anions including methotrexate | Trp1254 mutation abolishes methotrexate transport; role in drug resistance |
| ABCB1 (MDR1/P-gp) | ATP-dependent efflux pump for multiple drugs including methotrexate | Overexpression causes multidrug resistance; inhibitors can reverse resistance |
| ABCG2 (BCRP) | ATP-dependent efflux pump for methotrexate and other drugs | Contributes to drug resistance; target for inhibitors |
| SLC22A6 (OAT1) | Organic anion transporter involved in renal methotrexate secretion | Affects methotrexate clearance and toxicity |
| SLC22A8 (OAT3) | Organic anion transporter in kidney and brain | May influence methotrexate disposition |
| SLCO1B1 (OATP1B1) | Organic anion transporting polypeptide | Mediates hepatic uptake of methotrexate |
| SLCO1B3 (OATP1B3) | Organic anion transporting polypeptide | Contributes to methotrexate transport in liver |
| ABCC3 (MRP3) | Efflux pump for methotrexate and other organic anions | May affect drug resistance and pharmacokinetics |
| ABCC4 (MRP4) | Efflux pump for methotrexate and nucleotides | Role in methotrexate efflux and resistance |
| ABCG1 | ABC transporter with possible role in methotrexate transport | Less characterized; potential for research |
| SLC19A2 (ThTr1) | Thiamine transporter that can transport methotrexate when chimaerized with RFC | Used to study structure-function of RFC |
| SLC19A3 (ThTr2) | Thiamine transporter with folate transport activity | Potential role in methotrexate transport |
| FOLR1 (FRα) | Folate receptor that can mediate methotrexate uptake | Target for drug delivery |
| FOLR2 (FRβ) | Folate receptor with restricted expression | Potential for targeted therapy |
| GART | Enzyme in purine biosynthesis, not a transporter | Not directly related; included for context of methotrexate mechanism |
How Is methotrexate transmembrane transporter activity Regulated?
The activity of methotrexate transporters is regulated at multiple levels. Transcriptional regulation of SLC19A1 and SLC46A1 can be influenced by folate status and cellular stress. ABC transporters like ABCB1 and ABCG2 are subject to regulation by nuclear receptors and can be inhibited by small molecules such as sildenafil, which reverses drug resistance. Post-translational modifications, including phosphorylation, may also modulate transporter activity, though specific pathways for methotrexate transporters require further study.
methotrexate transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 | Multidrug resistance in cancer and autoimmune diseases | CRISPR knockout in K562 or HeLa cells; transport assays |
| ABCC2 | Methotrexate resistance due to loss of transport | Point mutation (Trp1254) knock-in in HepG2 or HEK293 cells |
| SLC19A1 | Methotrexate sensitivity and toxicity | Knockout in K562 cells; restoration with half-molecules |
| SLC46A1 | Intestinal methotrexate absorption | Knockout in Caco-2 cells; transport studies |
| ABCG2 | Drug resistance in cancer | Overexpression in HEK293 cells; inhibitor studies |
Cancer drug resistance
Altered methotrexate transport activity is a major mechanism of resistance to methotrexate and other chemotherapeutics. Overexpression of ABCB1 and ABCG2 efflux pumps reduces intracellular drug accumulation, leading to multidrug resistance. Conversely, loss of influx transporters such as RFC can also confer resistance. Mutations in ABCC2, such as Trp1254, abolish methotrexate transport and may contribute to resistance in certain cancers.
Autoimmune rheumatic diseases
Methotrexate is a first-line therapy for rheumatoid arthritis and other autoimmune diseases. P-glycoprotein (ABCB1) overexpression in lymphocytes has been associated with poor response to methotrexate in these patients, suggesting that efflux pump activity can limit drug efficacy.
Cystic fibrosis and emerging treatments
Methotrexate transport may be relevant in cystic fibrosis, where emerging treatments target the underlying CFTR defect. However, direct links between methotrexate transporters and cystic fibrosis are not well established.
From methotrexate transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC19A1 reduce methotrexate uptake? | CRISPR knockout of SLC19A1 in K562 cells followed by transport assays |
| Does the Trp1254 mutation in ABCC2 abolish methotrexate transport? | Point mutation knock-in of W1254X in HEK293 cells |
| Can co-expression of RFC half-molecules restore transport? | Knock-in of split RFC fragments in transport-impaired K562 cells |
| Does overexpression of ABCB1 confer methotrexate resistance? | Overexpression of ABCB1 in cancer cell lines |
| What is the role of PCFT transmembrane domain 2 in transport? | Cysteine accessibility and point mutations in SLC46A1 |
| Can chimaeric RFC/ThTr1 transporters restore activity? | Knock-in of chimaeric constructs in transport-deficient cells |
How to Study the methotrexate transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled transport assay | Uptake or efflux of methotrexate | Quantifying transporter activity in cell lines |
| Site-directed mutagenesis | Effect of specific amino acid changes on transport | Identifying critical residues like Trp1254 in MRP2 |
| CRISPR knockout | Loss of gene function on transport activity | Validating SLC19A1 as major methotrexate influx transporter |
| CRISPR knock-in | Restoration or alteration of transport activity | Introducing point mutations or chimaeric constructs |
| Cysteine accessibility assay | Solvent exposure of engineered cysteines | Mapping transmembrane topology of PCFT |
| ATPase assay | ATP hydrolysis by ABC transporters | Measuring activity of ABCB1, ABCG2, ABCC2 |
| Inhibitor profiling | Reversal of resistance by transport inhibitors | Testing sildenafil and other modulators |
| Expression profiling (RNA-seq) | Transcript levels of transporter genes | Correlating expression with drug response |
Transport assays
Radiolabeled methotrexate uptake or efflux assays are the gold standard for measuring transporter activity. These assays can be performed in cell lines expressing wild-type or mutant transporters to quantify kinetics and substrate specificity.
Mutagenesis and chimaera studies
Site-directed mutagenesis and chimaeric transporter construction help identify domains critical for methotrexate transport. For example, swapping transmembrane domains between RFC and ThTr1 revealed the importance of the TM6/7 linker, and cysteine accessibility mapped the PCFT reentrant loop.
CRISPR-based genome editing
CRISPR knockout, knock-in, and point mutations enable precise manipulation of transporter genes in relevant cell models. These models can be used to validate the contribution of specific genes to methotrexate transport and resistance.
Structural biology and computational modeling
Cryo-EM and homology modeling provide insights into the structural basis of methotrexate transport. These methods complement functional studies by visualizing substrate binding pockets and conformational changes.
How CRISPR Can Be Used to Study GO:0015350 methotrexate transmembrane transporter activity
Knockout
CRISPR knockout of transporter genes such as SLC19A1 or ABCC2 can abolish methotrexate transport activity, providing direct evidence of their role. For example, knockout of SLC19A1 in K562 cells reduces methotrexate uptake, and this can be rescued by expressing functional transporter fragments.
Point Mutation
Introducing specific point mutations, such as Trp1254 in ABCC2, via CRISPR knock-in allows researchers to study the impact on substrate specificity and transport activity. This approach mimics naturally occurring mutations and can reveal critical residues for methotrexate transport.
Knock-in
Knock-in of chimaeric transporters or split half-molecules can restore transport activity in deficient cells, helping to map functional domains. For instance, co-expression of RFC half-molecules in transport-impaired K562 cells restored methotrexate transport, localizing the substrate binding domain to transmembrane domains 7-12.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of transporters like ABCB1 or ABCG2 can model drug resistance by increasing efflux activity. Such models are useful for testing inhibitors that reverse resistance, such as sildenafil.
How EDITGENE Supports methotrexate transmembrane transporter activity Research
Researchers studying methotrexate transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in drug transport, resistance, or toxicity. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for methotrexate transmembrane transporter activity research.
Frequently Asked Questions About methotrexate transmembrane transporter activity
What is methotrexate transmembrane transporter activity?
It is a molecular function (GO:0015350) that enables the movement of methotrexate across cell membranes, mediated by specific transport proteins.
What genes are involved in methotrexate transmembrane transporter activity?
Key genes include SLC19A1 (RFC), SLC46A1 (PCFT), ABCC2 (MRP2), ABCB1 (MDR1), and ABCG2 (BCRP).
How is methotrexate transported into cells?
Methotrexate enters cells primarily via the reduced folate carrier (SLC19A1) and the proton-coupled folate transporter (SLC46A1).
What is the role of ABC transporters in methotrexate resistance?
ABC transporters such as ABCB1, ABCG2, and ABCC2 efflux methotrexate out of cells, reducing intracellular drug levels and contributing to resistance.
Can mutations in transporters affect methotrexate efficacy?
Yes, mutations like Trp1254 in ABCC2 can abolish methotrexate transport, leading to resistance.
How can CRISPR be used to study methotrexate transporters?
CRISPR knockout, knock-in, and point mutations allow precise editing of transporter genes to study their function in drug transport and resistance.
What diseases are associated with altered methotrexate transport?
Cancer drug resistance and autoimmune rheumatic diseases are linked to altered transport activity.
What methods measure methotrexate transport activity?
Radiolabeled transport assays, ATPase assays, and inhibitor profiling are commonly used.
Is methotrexate transport the same as folate transport?
They overlap but are distinct; many transporters recognize both, but GO:0015350 specifically refers to methotrexate.
How does EDITGENE support methotrexate transporter research?
EDITGENE provides CRISPR knockout, knock-in, point mutation, overexpression, and library screening services to model transporter function.
Conclusion
GO:0015350, methotrexate transmembrane transporter activity, is a critical molecular function that governs the cellular entry and exit of a widely used chemotherapeutic and immunosuppressive drug. The diversity of transporters involved, from RFC and PCFT to ABC efflux pumps, underscores the complexity of methotrexate pharmacology. Understanding these mechanisms is essential for predicting drug response, overcoming resistance, and developing new therapeutic strategies. CRISPR-based models offer powerful tools to dissect the contribution of individual transporters and to identify novel targets for modulating methotrexate activity.
References
- 1. Witt TL et al.. 2004. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12.. J Biol Chem 279(45):46755-63 PMID: 15337749
- 2. García-Carrasco M et al.. 2015. P-glycoprotein in autoimmune rheumatic diseases.. Autoimmun Rev 14(7):594-600 PMID: 25712147
- 3. Shi Z et al.. 2011. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.. Cancer Res 71(8):3029-41 PMID: 21402712
- 4. Matherly LH et al.. 2003. Membrane transport of folates.. Vitam Horm 66:403-56 PMID: 12852262
- 5. Ito K et al.. 2001. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity.. J Biol Chem 276(41):38108-14 PMID: 11500505
- 6. Liu XY et al.. 2003. Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the transmembrane domain 6/7 linker region in reduced folate carrier function.. Biochem J 369(Pt 1):31-7 PMID: 12227830
- 7. Wilson MR et al.. 2014. Substituted cysteine accessibility reveals a novel transmembrane 2-3 reentrant loop and functional role for transmembrane domain 2 in the human proton-coupled folate transporter.. J Biol Chem 289(36):25287-95 PMID: 25053408
- 8. Jones AM et al.. 2009. Emerging treatments in cystic fibrosis.. Drugs 69(14):1903-10 PMID: 19747007
